Armut & ProntoPro Merge and Raise €15 Million To Be the Leading Local Services Marketplace in EMEA
The European online local services have seen significant growth during the pandemic. Starting from early phases of the pandemic, people have given more importance to their houses. So, most of the customers started to look for online ways to improve their homes and personal needs. That helped to accelerate the growth of local services marketplaces like Armut and ProntoPro.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907005608/en/
Armut co-founder Erol Değim - Armut co-founder Başak Taşpınar Değim (Photo: Business Wire)
Founded in 2011, Armut operates in 8 countries with 2 brands in the EMEA region. The tech company has more than 700.000 service providers in 4.000 categories. Armut's all-in-one local services platform offers the full range of local services with ease and high levels of satisfaction today's consumers seek - whether that means getting your home painted, finding a math tutor for your child or finding an online psychologist. Similarly, ProntoPro aims to match customers and local service providers since 2015. The leader of the Italian market is growing in other 5 European countries, more than 5 million customers have been supported by 690.000 professionals.
New investment round of €15 million
Armut and ProntoPro’s explosive organic growth and modern take on local services enabled the merged company to raise €15 million in new funding. The round was led by ProntoPro’s investors. Armut had done previous investment rounds with European venture capital firms; Hummingbird and Addventure.
Armut co-founder Başak Taşpınar Değim said that the new funding will enable the company to triple its investment in product and headcount, expand services across all European markets, and pave the path toward this new company becoming the clear leading local services marketplace in Europe.
Armut co-founder Erol Değim wrote: “Our vision and the way we develop the product is very similar to ProntoPro. By joining forces together we’ll accelerate our growth and we’ll continue to create the best solutions for our customer's service needs.”
İstanbul and Milano headquarters will continue to grow their teams. Now the company has 206 employees from 22 nationalities and with the average age below 30. There will be new jobs opening in the following months in both headquarters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Gizem Ekiz | VP Marketing @Armut
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Announces Collaboration With Qore ® to Use QIRA ® for Next Generation Bio-derived LYCRA ® Fiber at Scale29.9.2022 02:00:00 CEST | Press release
The LYCRA Company,a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, today announced it has entered into an agreement with Qore® to enable the world’s first large-scale commercial production of bio-derived spandex using QIRA®, the next generation 1,4-butanediol (BDO), as one of its main ingredients. This will result in 70% of the LYCRA® fiber content being derived from annually renewable feedstock. This change could potentially reduce the carbon footprint of LYCRA® fiber by up to 44%* versus equivalent product made from fossil-based resources, while maintaining the same high-quality performance parameters of traditional LYCRA® fiber. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005020/en/ The LYCRA Company signs an agreement with Qore® LLC to enable large-scale production of bio-derived spandex. Pictured – Julien Born, CEO of The LYCRA Company (left), and Jon
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation ™28.9.2022 22:30:00 CEST | Press release
Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodulation,further establish the efficacy and safety of ReActiv8 Restorative Neurostimulation, including compelling long-term durability and improvement over time on key outcome measures in the treatment of intractable chronic low back pain. The three-year data show improvements over results from the patients’ one-year and two-year visits on virtually all key efficacy measures. Of note: Outcome measure 1-year result (N = 176) 2-year result (N = 156) 3-year result (N = 133) Patients reporting pain intensity (Visual Analog Scale (VAS) score) reduced by 50% or more from baseline 64% 71% 77% Patients reporting a greater than 20-point reduction in Oswestry Disability Index 57% 61% 63% Patients reporting VAS score < 2.5 52% 65% 67% Patients taking opioids at basel
New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release
Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money
BYD Announces Pre-sale Prices of European Passenger Car Range28.9.2022 15:35:00 CEST | Press release
BYD announces the pre-sale prices of its new European passenger car range. The world’s leading manufacturer of new energy vehicles and power batteries immediately introduces three full-electric passenger vehicles which will be delivered to Norway, Sweden, Denmark, the Netherlands, Belgium, Luxembourg and Germany. Before the end of the year customers in France and the United Kingdom will also have access to BYD’s zero-emission vehicles. After that, more dealers will be appointed supporting BYD’s plans to cover all major markets in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005587/en/ BYD Europe Product Premiere 2022 The pre-sale price for the BYD ATTO 3 is € 38,000. The BYD HAN and TANG pre-sale prices are € 72,000. These pre-sale prices apply to Germany as a reference for Europe and may differ from country to country. The three full-electric BYD vehicles are technologically advanced and well-suited to the e
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany28.9.2022 15:27:00 CEST | Press release
Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services. Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros. (*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom